Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hematopoietic cell transplant offers realistic cure in secondary AML

Key clinical point: Consider allogeneic hematopoietic cell transplantation in eligible patients with secondary acute myeloid leukemia (AML).

Major finding: The projected 5-year overall survival was 48% for patients with secondary AML in first complete remission who underwent allogeneic hematopoietic cell transplantation, compared with 20% in patients who underwent chemotherapy consolidation (P = .01).

Study details: An observational study using data from the Swedish AML Registry comprising 3,337 intensively treated adult patients.

Disclosures: The study was supported by the Swedish Cancer Foundation, Swedish Research Council, Stockholm County Council, Gothenberg Medical Society, and Assar Gabrielsson Foundation. The researchers reported having no conflicts of interest.

Citation:

Nilsson C et al. Biol Blood Marrow Transplant. 2019;25:1770-8.